IBIO
iBio, Inc.
Next earnings Sep 3, 2026 · consensus $-0.07 EPS, $58.3K rev
Last earnings -3.0% on 2026-05-12
$1.67
▲ +5.03%$1.67▲ +135.21%
over 1Y
L $0.57EODHDH $3.07
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.0%
1W-4.0%
1M-11.2%
3M-5.1%
YTD-17.3%
1Y+135.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Revenue grew 77.8% YoY; but unprofitable (net margin -4594.3%).
Revenue (FY2025) $400K · FY2025
iBio, Inc. shows $400K in FY2025 revenue (+77.8% YoY), a -4594.3% net margin, and -123.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $225K | $400K |
| Gross profit | $909K | $2.17M | — | — | — |
| Operating income | -$31.1M | -$29.7M | -$29.3M | -$16.6M | -$18.6M |
| Net income | -$23.2M | -$50.3M | -$65.0M | -$24.9M | -$18.4M |
| Diluted EPS | -$3.00 | -$5.78 | -$106.19 | -$6.50 | -$1.75 |
| Net margin | — | — | — | -11069.8% | -4594.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$24.2M
EV / EBITDA—
EV / Sales60.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-56.0%
FCF yield-46.7%
Quality & risk
ROIC (est.)-98.8%
Free cash flow-$15.3M
Total debt—
Net cash$8.58M
Altman Z-Score-20.13 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+127.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-02-27). Worth a closer look.
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- 8-K Officer / director change2026-05-08
- 8-K/A Amended 8-K2026-04-17
- 8-K Reg FD disclosure2026-04-08
- 8-K Reg FD disclosure2026-03-09
- 8-K Agreement terminated2026-02-27
- S-3 Shelf registration (potential raise)2026-02-27
- 8-K Earnings results2026-02-10
Recent filings
all on EDGAR ↗4Period ending 2026-05-182026-05-19open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗3Period ending 2026-05-072026-05-15open ↗SCHEDULE 13G/AFiling2026-05-14open ↗SCHEDULE 13G/AFiling2026-05-12open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗8-KPeriod ending 2026-05-072026-05-08open ↗
Frequently asked
- Is iBio, Inc. (IBIO) a buy?
- IBIO currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 77.8% YoY; but unprofitable (net margin -4594.3%).
- What is iBio, Inc.'s quality score?
- IBIO scores 47.745098039215684/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001420720, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:55:26 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.